← Back to Search

Unknown

AB-2004 for Autism Spectrum Disorder

Phase 2
Waitlist Available
Research Sponsored by Axial Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing AB-2004 to see if it can safely and effectively reduce irritability in people with autism spectrum disorder by changing their gut bacteria.

Eligible Conditions
  • Autism Spectrum Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AB-2004Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Axial Therapeutics, Inc.Lead Sponsor

Media Library

AB-2004 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT04895215 — Phase 2
Autism Spectrum Disorder Research Study Groups: AB-2004, Placebo
Autism Spectrum Disorder Clinical Trial 2023: AB-2004 Highlights & Side Effects. Trial Name: NCT04895215 — Phase 2
AB-2004 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04895215 — Phase 2
~36 spots leftby Dec 2025